Literature DB >> 1903527

Quality control programme for the preparation of small-pool lyophilized heat-treated cryoprecipitates.

D P Allersma1, F Swüste, E Briët, J A Van der Does.   

Abstract

International and national documents on and standards for quality control have been introduced for Blood Banks. Recently, the Standard Registration Document and a National Health Authority Licence for factor VIII preparations based on the Document were introduced in the Netherlands. In the course of developing a preparation of lyophilized heat-treated cryoprecipitates in our Blood Bank, we used this Standard Registration Document and the good pharmaceutical manufacturing practices to design a quality control protocol. The aim of this protocol was to provide documented evidence on the quality of both our product and the production process. The protocol included the validation or revalidation of individual installations and procedures used during production, validation of the whole process and quality control of routine production. With our quality protocol we have been able to demonstrate that our preparation is consistently of the intended quality.

Mesh:

Substances:

Year:  1991        PMID: 1903527     DOI: 10.1007/bf01963880

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  10 in total

1.  [Rapid physiological coagulation method in determination of fibrinogen].

Authors:  A CLAUSS
Journal:  Acta Haematol       Date:  1957-04       Impact factor: 2.195

2.  Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis.

Authors:  D P Allersma; E Roeffen; J A Van der Does; E Briët
Journal:  Pharm Weekbl Sci       Date:  1991-02-22

3.  Determination of serum proteins by means of the biuret reaction.

Authors:  A G GORNALL; C J BARDAWILL; M M DAVID
Journal:  J Biol Chem       Date:  1949-02       Impact factor: 5.157

4.  Freezing of plasma and recovery of factor VIII.

Authors:  G Carlebjörk; M Blombäck; P Pihlstedt
Journal:  Transfusion       Date:  1986 Mar-Apr       Impact factor: 3.157

5.  The effects of temperature variations on cryoprecipitate.

Authors:  G A Rock; P Tittley
Journal:  Transfusion       Date:  1979 Jan-Feb       Impact factor: 3.157

6.  In vitro and in vivo characterization of factor VIII preparations.

Authors:  J P Allain; F Verroust; J P Soulier
Journal:  Vox Sang       Date:  1980-02       Impact factor: 2.144

7.  What are the critical factors in the production and quality control of frozen plasma intended for direct transfusion or for fractionation to provide medically needed labile coagulation factors?

Authors: 
Journal:  Vox Sang       Date:  1983       Impact factor: 2.144

8.  Contribution to the optimal use of human blood. VII. Increase of the yield of factor VIII in four-donor cryoprecipitate by an improved processing of blood and plasma.

Authors:  C Vermeer; B A Soute; G Ates; H G Brummelhuis
Journal:  Vox Sang       Date:  1976       Impact factor: 2.144

9.  A calculator program for individualizing factor VIII dosage.

Authors:  G Longo; M Matucci; M Morfini; S Vannini; A Messori
Journal:  Drug Intell Clin Pharm       Date:  1984-09

Review 10.  Clinical pharmacokinetics of factor VIII in patients with classic haemophilia.

Authors:  A Messori; G Longo; M Matucci; M Morfini; P L Ferrini
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

  10 in total
  1 in total

1.  Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis.

Authors:  D P Allersma; E Roeffen; J A Van der Does; E Briët
Journal:  Pharm Weekbl Sci       Date:  1991-02-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.